EGFR and cancer: As a ligand of EGFR, s-HBEGF has been previously proposed as a promising target of several cancers in literature.75–77 Applying HBEGF neutralizing antibody or inhibiting the release of s-HBEGF may improve the clinical outcomes of patients under anticancer therapy.